Human variants of O6-alkylguanine-DNA alkyltransferase

Anthony E. Pegg; Qingming Fang; Natalia A. Loktionova

doi:10.1016/j.dnarep.2007.03.012

Human variants of O⁶-alkylguanine-DNA alkyltransferase

Anthony E. Pegg, Qingming Fang, Natalia A. Loktionova

Research output: Contribution to journal › Review article › peer-review

59 Scopus citations

Abstract

This article summarizes the current understanding of known variant forms of the MGMT gene that encode an altered protein. Epidemiological studies have been carried out to test whether these alterations are associated with altered cancer risk. Laboratory studies using recombinant proteins and cells expressing the known variants have investigated the possible effects of these sequence alterations on the ability of the encoded O⁶-alkylguanine-DNA alkyltransferase protein to protect cells from alkylation damage and to respond to therapeutic inactivators currently undergoing trials for cancer chemotherapy.

Original language	English (US)
Pages (from-to)	1071-1078
Number of pages	8
Journal	DNA Repair
Volume	6
Issue number	8
DOIs	https://doi.org/10.1016/j.dnarep.2007.03.012
State	Published - Aug 1 2007

All Science Journal Classification (ASJC) codes

Biochemistry
Molecular Biology
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.dnarep.2007.03.012

Cite this

@article{7b566db5c3404a10b26e555faadfd6bc,

title = "Human variants of O6-alkylguanine-DNA alkyltransferase",

abstract = "This article summarizes the current understanding of known variant forms of the MGMT gene that encode an altered protein. Epidemiological studies have been carried out to test whether these alterations are associated with altered cancer risk. Laboratory studies using recombinant proteins and cells expressing the known variants have investigated the possible effects of these sequence alterations on the ability of the encoded O6-alkylguanine-DNA alkyltransferase protein to protect cells from alkylation damage and to respond to therapeutic inactivators currently undergoing trials for cancer chemotherapy.",

author = "Pegg, {Anthony E.} and Qingming Fang and Loktionova, {Natalia A.}",

note = "Funding Information: This work was supported by grants CA-018137 and CA-071976 from the National Cancer Institute, National Institutes of Health, USA.",

year = "2007",

month = aug,

day = "1",

doi = "10.1016/j.dnarep.2007.03.012",

language = "English (US)",

volume = "6",

pages = "1071--1078",

journal = "DNA Repair",

issn = "1568-7864",

publisher = "Elsevier B.V.",

number = "8",

}

TY - JOUR

T1 - Human variants of O6-alkylguanine-DNA alkyltransferase

AU - Pegg, Anthony E.

AU - Fang, Qingming

AU - Loktionova, Natalia A.

N1 - Funding Information: This work was supported by grants CA-018137 and CA-071976 from the National Cancer Institute, National Institutes of Health, USA.

PY - 2007/8/1

Y1 - 2007/8/1

N2 - This article summarizes the current understanding of known variant forms of the MGMT gene that encode an altered protein. Epidemiological studies have been carried out to test whether these alterations are associated with altered cancer risk. Laboratory studies using recombinant proteins and cells expressing the known variants have investigated the possible effects of these sequence alterations on the ability of the encoded O6-alkylguanine-DNA alkyltransferase protein to protect cells from alkylation damage and to respond to therapeutic inactivators currently undergoing trials for cancer chemotherapy.

AB - This article summarizes the current understanding of known variant forms of the MGMT gene that encode an altered protein. Epidemiological studies have been carried out to test whether these alterations are associated with altered cancer risk. Laboratory studies using recombinant proteins and cells expressing the known variants have investigated the possible effects of these sequence alterations on the ability of the encoded O6-alkylguanine-DNA alkyltransferase protein to protect cells from alkylation damage and to respond to therapeutic inactivators currently undergoing trials for cancer chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=34447330982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447330982&partnerID=8YFLogxK

U2 - 10.1016/j.dnarep.2007.03.012

DO - 10.1016/j.dnarep.2007.03.012

M3 - Review article

C2 - 17482892

AN - SCOPUS:34447330982

SN - 1568-7864

VL - 6

SP - 1071

EP - 1078

JO - DNA Repair

JF - DNA Repair

IS - 8

ER -